Agile therapeutics announces peer-reviewed publication of phase 3 secure study results for twirla® (levonorgestrel and ethinyl estradiol) transdermal system in contraception

Princeton, n.j., nov. 30, 2020 (globe newswire) -- agile therapeutics, inc. (nasdaq: agrx), a women's healthcare company, today announced that contraception, an international, peer-reviewed, reproductive health journal, published the primary safety, efficacy, and tolerability results from the phase 3 secure study evaluating twirla® (levonorgestrel and ethinyl estradiol) transdermal system. the results have been published online in contraception (https://bit.ly/securestudy) and will also appear in a future print edition of the journal.
AGRX Ratings Summary
AGRX Quant Ranking